Direct versus indirect thrombin inhibition in percutaneous coronary intervention

Journal of Invasive Cardiology

Volumn 14, Issue SUPPL. B, 2002, Pages

  Marmur, Jonathan D ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ARGATROBAN; DESULFATOHIRUDIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN DERIVATIVE; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; THROMBIN INHIBITOR;

BLEEDING; CARDIOLOGY; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DRUG ACTIVITY; DRUG HALF LIFE; DRUG MECHANISM; HEPARINIZATION; HUMAN; INTERVENTIONAL RADIOLOGY; PHARMACODYNAMICS; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; WHOLE BLOOD COAGULATION TIME;

EID: 0036220923     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Nonoperative dilatation of coronary artery stenosis
2. Production and chemical processing of low molecular weight heparins
3. Heparin
4. Correlation between structure and function of heparin
5. The heparin-antithrombin system: A natural anticoagulant mechanism
6. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti Xa activity
7. Extension and structural variability of the antithrombin-binding sequence in heparin
8. Contribution of 3-0- and 6-0-sulfated glycosamine residues in the heparin induced conformational change in antithrombin III
9. Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and hirudin
10. Heparin and low molecular weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety
11. Protection of factor Xa from neutralization by the heparin-antithrombin complex
12. Binding and endocytosis of heparin by human endothelial cells in culture
13. Vascular sequestration of heparin
14. Studies on the heparin sulphamidase activity from rat spleen: Intracellular distribution and characterization of the enzyme
15. Kinetics of intravenously administered heparin in normal humans
16. The elimination from plasma of intravenous heparin: An experimental study on dogs and humans
17. Heparin kinetics determined by three assay methods
18. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
19. Inability of the activated partial thromboplastin time to predict heparin levels
20. Heparin binding to plasma proteins, an important mechanism for heparin resistance
21. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin
22. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
23. Human thrombi contain an abundance of active thrombin
24. Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab
25. Heparin-induced thrombocytopenia. Diagnosis, natural history, and treatment options
26. Low-molecular-weight heparins in non-ST segment elevation ischemia: The ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events) trial
27. Defining the optimal ACT during percutaneous coronary intervention: Aggregate results from six randomized controlled trials
28. Mechanisms of action of low molecular weight heparins and heparinoids
29. Low-molecular-weight heparins
30. Molecular weight dependency of heparin potentiated inhibition of thrombin and activated factor X: Effect of heparin neutralization in plasma
31. Role of ternary complexes in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa
32. High active heparin species with multiple binding sites for antithrombin
33. Heparin with two binding sites for antithrombin or platelet factor 4
34. New anticoagulants
35. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin
36. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis
37. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4
38. Neutralization and binding of heparin by S-protein/vitronectin in the inhibition of factor Xa by antithrombin III
39. Sequestration of therapeutic glycosaminoglycans by plasma fibronectic
40. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo
41. Heparin binding and neutralizing protein
42. Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture
43. Heparin degradation in the endothelial cells
44. Pharmacokinetics of low molecular weight heparins in animal models
45. Disappearance of circulating anti-Xa activity after intravenous injection of unfractionated heparin and of low molecular weight beparin (CY216) in normal and nephrectomized rabbits
46. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance
47. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin
48. Low-dose heparin for routine coronary angioplasty and stenting
49. A randomized trial of a fixed high dose vs. a weight-adjusted low dose of intravenous heparin during coronary angioplasty
50. Relation between activated clotting time during angioplasty and abrupt closure
51. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty
52. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty
53. Putting heparin into perspective: Its history and the evolution of its use during percutaneous coronary intervention
54. Relation between abrupt vessel closure and the anticoagulant response to beparin or bivalirudin during coronary angioplasty
55. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor
56. Increased platelet responsiveness following coronary stenting. Heparin as a possible aetiological factor in stent thrombosis
57. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
58. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention
59. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization
60. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
61. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist C7e3 fab on the activated clotting time
62. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: Evidence for a complex interaction in a multicenter trial
63. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting) trial diabetic substudy
64. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomized, placebo controlled trial
65. The use of glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary intervention
66. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
67. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
68. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first"
69. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention
70. The use of enoxaparin and GP IIb/IIIa antagonists in acute coronary syndromes. Final results of the NICE 3 study
71. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty
72. Thrombin inhibition by hirudin: How hirudin inhibits thrombin
73. Kinetics of the inhibition of thrombin by hirudin
74. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin
75. Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation - Organization to assess strategies for ischemic syndromes (OASIS-2) study
76. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q wave myocardial infarction: Organization to assess strategies for ischemic syndromes (OASIS) pilot study results
77. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial
78. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty
79. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
80. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK)
81. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial
82. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
83. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study
84. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
85. Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia
86. Results of a phase 2/3 trial of argatroban anticoagulation during PTCA of patients with heparin-induced thrombocytopenia
87. Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome
88. The thrombin-specific anticoagulant, bivalirudin, completely inhibits thrombin-mediated platelet aggregation
89. Thrombin signalling and protease-activated receptors
90. Role of thrombin signalling in platelets in haemostasis and thrombosis
91. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty
92. Bivalirudin for percutaneous coronary interventions: Development perspective
93. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: The final report of the bivalirudin angioplasty study
94. Clinical outcomes of bivalirudin for ischemic heart disease